Previous 10 | Next 10 |
PG&E (NYSE: PCG ) -29% on bankruptcy judge decision clearing way for Elliott plan. More news on: PG&E Corporation, Forescout Technologies, Inc., HEXO Corp., Stocks on the move, Read more ...
Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients – No reported drug-related serious adverse events – Achieved marked reduction in Bullous Pemphigoid Disease Ar...
NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, tod...
The following slide deck was published by Akari Therapeutics, Plc in conjunction with this Read more ...
The FDA has granted Orphan Drug Designation to Akari Therapeutics' (NASDAQ: AKTX ) nomacopan for the treatment of bullous pemphigoid (BP). More news on: Akari Therapeutics, Plc, Healthcare stocks news, Stocks on the move, Read more ...
NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, tod...
Intelsat (NYSE: I ) -11% . More news on: Intelsat S.A., T2 Biosystems, Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, tod...
SeaChange International (NASDAQ: SEAC ) +24% on Q2 results . More news on: SeaChange International, Inc., Ambarella, Inc., Akari Therapeutics, Plc, Stocks on the move, Read more ...
The FDA has granted orphan drug designation to Akari Therapeutics' (NASDAQ: AKTX ) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). More news on: Akari Therapeutics, Plc, Healthcare stocks news, Read more .....
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies...
Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophth...